Predicting GLP-1 treatment response
A London Life Sciences Week event hosted by PrecisionLife & Ovation
Learn how we predict GLP-1 treatment response and are shaping the future of precision medicine
Join an exclusive panel discussion hosted by PrecisionLife and Ovation at London's stunning life sciences hub, Victoria House.
Learn how world-leading AI, genomics and multi-omics are transforming biomarker discovery, clinical reporting and personalized medicine.
A central focus will be the new GLP-1 Genetic Response report, designed to predict strong and weak responders for weight loss, with commercial launch in 2027.
The discussion will address the significant commercial and clinical opportunities, including:
- Pharmaceutical applications: Biomarker discovery, drug development and more targeted clinical trial enrollment.
- Precision diagnostics: Predictive testing for treatment response and personalized therapy selection.
- Payer applications: Evidence-based patient stratification to improve treatment outcomes and optimize reimbursement and healthcare costs.
- Scalable discovery: Leveraging AI and multi-omics to develop clinically actionable biomarkers across complex chronic diseases.
Panelists include:
Steve Gardner
Chief Executive Officer, PrecisionLife
Chief Executive Officer, PrecisionLife
Pat Gallagher
Head of Multiomics, Ovation
Head of Multiomics, Ovation
Rowan Gardner
Chief Business & Investment Officer, PrecisionLife
Chief Business & Investment Officer, PrecisionLife
Rainer Metzger
Head of Precision Medicine & Precision Diagnostics, Ovation
Head of Precision Medicine & Precision Diagnostics, Ovation
THIS EVENT IS NOW FULL
📅 10:00 AM | Tuesday 17 November
📍Victoria House, Bloomsbury Square, London

